-
Mashup Score: 6
ARS Pharma has submitted a response letter to the FDA as it seeks approval for its neffy epinephrine nasal spray, which is designed to treat type I allergic reactions such as anaphylaxis, according to a company press release. “Based on multiple meetings with the FDA, we believe that we have responded fully and completely to the agency’s concerns and appreciate its insights along the
Source: www.healio.comCategories: General Medicine News, Allergy-ImmunologyTweet
ARS Pharma has sent a reply to the FDA following a new study on nasal epinephrine. Stay updated! #Healthcare #FDAApproval https://t.co/hwpWkLV9Wm https://t.co/Ivq5qr6pH0